Page last updated: 2024-12-06

2,4-diaminopyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-Diaminopyrimidine is a heterocyclic organic compound with the formula C4H6N4. It is a white solid that is soluble in water. 2,4-diaminopyrimidine is an important intermediate in the synthesis of many drugs, including the antimalarial drug pyrimethamine and the anti-inflammatory drug sulfasalazine. It is also used in the synthesis of other organic compounds, such as dyes and pesticides. 2,4-diaminopyrimidine has been shown to have a variety of biological effects, including antibacterial, antifungal, and antiviral activity. It is also known to be a potent inhibitor of dihydrofolate reductase, an enzyme that is essential for the synthesis of DNA and RNA. The importance of 2,4-diaminopyrimidine lies in its diverse applications in the synthesis of pharmaceuticals, dyes, and other organic compounds. Its potent biological activity, particularly its ability to inhibit dihydrofolate reductase, has led to its extensive study in the fields of medicine and drug development. '

2,6-diaminopyrimidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyrimidine-2,4-diamine : An aminopyrimidine in which a pyrimidine nucleus is substituted with amino groups at C-2 and C-4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID67431
CHEMBL ID1233987
CHEBI ID43745
SCHEMBL ID53016
SCHEMBL ID12500595
SCHEMBL ID18583192
MeSH IDM0067793

Synonyms (49)

Synonym
CHEMBL1233987
diaminopyrimidine
pyrimidine-2,4-diamine
nsc30856
156-81-0
wln: t6n cnj bz dz
nsc-30856
pyrimidine,4-diamino-
2,4-pyrimidinediamine
lg3 ,
inchi=1/c4h6n4/c5-3-1-2-7-4(6)8-3/h1-2h,(h4,5,6,7,8
2,4-diaminopyrimidine, 98%
2,4-diaminopyrimidine ,
D2120
A3445
AKOS009156371
2,6-diaminopyrimidine
l5zy0jjp5j ,
pyrimidine-2,4-diyldiamine
nsc 30856
unii-l5zy0jjp5j
pyrimidine, 2,4-diamino-
einecs 205-862-3
FT-0609974
PS-4817
AM20080406
SCHEMBL53016
2,4-diamino-pyrimidine
2,4-pyrmidinediamine
cytosine imine
W-201413
SCHEMBL12500595
pyrimidine, 2,4-diamine
DTXSID70166021
CS-W005124
mfcd00038023
2,4-diaminopyrimidine, technical grade
SCHEMBL18583192
8-azacytosine
iminodihydropyrimidinimine
4-hydroxy-naphthalene-1-carboxylicacidmethylester
Q209196
CHEBI:43745
SY014486
SB57571
bdbm50542901
2,4-diaminopyrimidine-3n-oxide
EN300-154949
Z856211450

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" An orally bioavailable analogue (18) that displayed antitumor efficacy in ALCL xenograft models in mice was identified and extensively profiled."( Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.
Aimone, LD; Albom, MS; Angeles, TS; Anzalone, AV; Ator, MA; Burke, JP; Cheng, M; Dorsey, BD; Dugan, BJ; Huang, Z; Lu, L; Mesaros, EF; Ott, GR; Parrish, JD; Quail, MR; Ruggeri, BA; Wan, W, 2011
)
0.62
" Tumor stasis (with partial regressions) were observed when an orally bioavailable analog was evaluated in a GTL-16 tumor xenograft mouse model."( 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
Aimone, LD; Albom, MS; Angeles, TS; Brown, RA; Dorsey, BD; Galinis, D; Grobelny, JV; Herbertz, T; Husten, J; Kocsis, LS; LoSardo, C; Miknyoczki, SJ; Murthy, S; Rolon-Steele, D; Theroff, JP; Underiner, TL; Wells-Knecht, KJ; Worrell, CS; Zeigler, KS; Zificsak, CA, 2011
)
1.81
" Tumor growth inhibition was observed when an orally bioavailable analog was evaluated in a Karpas-299 tumor xenograft mouse model."( Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors.
Aimone, LD; Albom, MS; Angeles, TS; Cheng, M; Dorsey, BD; Mesaros, EF; Ott, GR; Quail, MR; Theroff, JP; Underiner, TL; Wan, W; Zificsak, CA, 2011
)
0.62
" In particular, certain-3-amidobenzazepin-2-one analogs had improved oral bioavailability and were evaluated in PK/PD and efficacy models."( Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
Aimone, LD; Albom, MS; Angeles, TS; Chang, H; Dorsey, BD; Grobelny, JV; Husten, J; Losardo, C; Miknyoczki, S; Milkiewicz, KL; Murthy, S; Rolon-Steele, D; Underiner, TL; Weinberg, LR; Worrell, CS; Zeigler, KS, 2011
)
0.64
" Pharmacokinetic studies indicated that the oral bioavailability of compound 19k is 17."( Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold.
Cheng, M; Liu, N; Lv, R; Qin, Q; Sun, Y; Wang, R; Wu, T; Yin, W; Zhang, C; Zhao, D, 2022
)
0.94

Dosage Studied

ExcerptRelevanceReference
" Brief clinical characteristics of sulfation, its administration routes, doses, dosage advantages and better tolerance as compared to co-trimethoxazole+ (biseptol) are described."( [A new drug sulfaton in the combined treatment of infections with sulfanilamide derivatives and diaminopyrimidine].
Padeĭskaia, EN, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseHomo sapiens (human)Ki180.00000.00000.37564.9000AID1660990
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1660996Selectivity index, ratio of Ki for Escherichia coli DHFR to Ki for human DHFR2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID1660990Inhibition of human DHFR in presence of DHF and NADPH by UV-vis spectrometry by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID1660993Inhibition of Escherichia coli DHFR2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID1660994Inhibition of Lactobacillus casei DHFR2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID575146Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolate NRS123 by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.
AID1660995Selectivity index, ratio of Ki for Lactobacillus casei DHFR to Ki for human DHFR2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID575144Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolate NRS1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (103)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (16.50)18.7374
1990's10 (9.71)18.2507
2000's11 (10.68)29.6817
2010's50 (48.54)24.3611
2020's15 (14.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.51 (24.57)
Research Supply Index4.66 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.96%)5.53%
Reviews1 (0.96%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other102 (98.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]